* Disseminated on behalf of ARMR Sciences Inc.
* For Accredited Investors Only. Offered pursuant to Rule 506(c). Reasonable steps to verify accreditation will be taken before any sale.
PAID ADVERTISEMENT – SPONSORED CONTENT
Fentanyl is no longer just another opioid – it has become the single most lethal synthetic drug in the United States. Since 2000, it is estimated that more than 20 million nonfatal overdoses have occurred in the U.S.- surpassing deaths from COVID-19, HIV/AIDS, and even major wars.
Today, fentanyl is the leading cause of death for adults aged 18–45, claiming an estimated 220 lives every single day.
A Silent, Rapid Killer
A minuscule amount – equivalent in size to just a few grains of salt – can be fatal. Fentanyl is fast-acting and often hidden in counterfeit pills or laced into drugs without the user’s knowledge.
Fentanyl is cheap to manufacture and covertly laced with counterfeit pills and recreational drugs. This stealth factor explains why the vast majority of overdose victims never intended to take fentanyl.
The financial toll is also staggering: the opioid epidemic costs the U.S. economy an estimated $2.7 trillion in 2023 alone, with cumulative losses exceeding $10 trillion over the past two decades.
Why Current Defenses Fall Short
Tools like naloxone (Narcan) have saved lives but remain purely reactive. They only work after an overdose begins and often fail against emerging analogs such as xylazine, nitazenes, or medetomidine, which Narcan cannot reverse. First responders, military personnel, and even families are left without effective long-term defenses.
ARMR’s Preventive Approach
ARMR Sciences is advancing its novel immunotherapy, ARMR-100, designed to train the immune system to block fentanyl before it reaches the brain. In preclinical (animal) studies, ARMR-100 blocked 92% of fentanyl’s entry into the brain and eliminated its addictive behavioral effects (at this stage ARMR-100 is not FDA-approved, human safety and efficacy have not been established, and preclinical results may not predict clinical outcomes).
Unlike reactive antidotes, this would provide months of protection – functioning like a biochemical shield.
The program is building on seven years of U.S. Department of Defense–funded research and is working to leverage proven vaccine components, such as carrier proteins already approved in licensed products and adjuvants tested in hundreds of clinical trials.
The Market and ARMR’s Mission
The potential reach is vast: 2.7 million Americans with opioid use disorder, over 2 million first responders and law enforcement officers, more than 18 million military personnel and veterans who experience higher rates of opioid use, chronic pain, and post-traumatic stress disorder, and more than 30 million high-risk young people.
A once or twice annual preventive shot could help transform national defense against fentanyl, making protection scalable across households, schools, hospitals, and security agencies.
The fentanyl crisis is no longer just a health issue – it’s a national security emergency. And we believe prevention, not rescue, may be the only path to saving a generation.
Why Investors Should Pay Attention
ARMR is more than a biotech startup – it is working to tackle America’s most urgent social and health crisis. This is a mission-driven company focused on building a preventive defense platform that could save thousands of lives each year:
- $30M private raise launched
- Seven years of DoD-backed research form the foundation
- Lead candidate ARMR-100 blocked 92% of fentanyl from entering the brain in preclinical studies
- A targeted exchange listing in the future
By investing in this round, investors have a chance to back a company whose mission is as much about impact as it is about growth potential.
For Accredited Investors Only. This offering is made pursuant to Rule 506(c) of Regulation D. All purchasers must be accredited investors, and the issuer will take reasonable steps to verify accredited status before any sale. Investing involves high risk, including the potential loss of your entire investment.
This is a paid advertisement for ARMR’s private offering. Please read the details of the offering at InvestARMR.com for additional information on the company and the risk factors related to the offering.
For investors from Canada: This advertisement forms part of the issuer’s marketing materials and is incorporated by reference into the issuer’s Offering Memorandum/Private Placement Memorandum under NI 45-106. Investors must receive and review the OM/PPM and execute the prescribed Form 45-106F4 Risk Acknowledgement before subscribing.
DISCLOSURES & DISCLAIMERS
CLIENT CONTENT: Carboncredits.com is not responsible for any content hosted on ARMR Sciences’ sites; it is ARMR Sciences’ responsibility to ensure compliance with applicable laws.
NOT INVESTMENT ADVICE: Content is for educational, informational, and advertising purposes only and should NOT be construed as securities-related offers or solicitations. All content should be considered promotional and subject to disclosed conflicts of interest.
Do NOT rely on this as personalized investment advice. Do your own due diligence.
Carboncredits.com strongly recommends you consult a licensed or registered professional before making any investment decision.
REGULATORY STATUS: Neither Carboncredits.com nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor, or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization.
CONTENT & COMPENSATION DISCLOSURE: Carboncredits.com has received compensation of thirty thousand dollars from ARMR Sciences for this sponsored content. You should assume we receive compensation as indicated for any purchases through links in this article via affiliate relationships, direct/indirect payments from companies or third parties who may own stock in or have other interests in promoted companies. We may purchase, sell, or hold long or short positions without notice in securities mentioned in this communication.
RESULTS NOT TYPICAL: Past performance and results are unverified and NOT indicative of future results. Results presented are NOT guaranteed as TYPICAL. Market conditions and individual circumstances vary significantly. Actual results will vary widely. Investing in securities is speculative and carries high risk; you may lose some, all, or possibly more than your original investment.
HIGH-RISK: Securities discussed may be highly speculative investments subject to extreme volatility, limited liquidity, and potential total loss. The Securities are suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time. No public market currently exists for the securities, and if a public market develops, it may not continue.
CAUTIONARY STATEMENT: Certain statements in this presentation (the “Presentation”) may be deemed to be “forward-looking statements” within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor provisions for forward-looking statements. Such forward-looking statements can be identified by the use of words such as ”should,” ”may,” ”intends,” ”anticipates,” ”believes,” ”estimates,” ”projects,” ”forecasts,” ”expects,” ”plans,” and ”proposes.” Forward-looking statements, which are based on the current plans, forecasts and expectations of management of ARMR Sciences Inc. (the “Company” or “ARMR Sciences”), are inherently less reliable than historical information. Forward-looking statements are subject to risks and uncertainties, including events and circumstances that may be outside our control.
Although management believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. Risks and uncertainties that could cause actual results to differ materially include, without limitation, those risks identified in the Private Placement Memorandum. Forward-looking statements speak only as of the date of the document in which they are contained, and ARMR Sciences Inc. does not undertake any duty to update any forward-looking statements except as may be required by law.
Any forward-looking financial forecasts contained in this Presentation are subject to a number of risks and uncertainties, and actual results may differ materially. You are cautioned not to place undue reliance on such forecasts. No assurances can be given that the future results indicated, whether expressed or implied, will be achieved. While sometimes presented with numerical specificity, all such forecasts are based upon a variety of assumptions that may not be realized, and which are highly variable. Because of the number and range of the assumptions underlying any such forecasts, many of which are subject to significant uncertainties and contingencies that are beyond the reasonable control of the issuing company, many of the assumptions inevitably will not materialize and unanticipated events and circumstances may occur subsequent to the date of any financial forecast.
Disclosure: Owners, members, directors, and employees of carboncredits.com have/may have stock or option positions in any of the companies mentioned: None.
Carboncredits.com receives compensation for this publication and has a business relationship with any company whose stock(s) is/are mentioned in this article.
Additional disclosure: This communication serves the sole purpose of adding value to the research process and is for information only. Please do your own due diligence. Every investment in securities mentioned in publications of carboncredits.com involves risks that could lead to a total loss of the invested capital.